Revance Therapeutics (Revance Therapeutics) EV-to-EBITDA : -1.92 (As of May. 15, 2024)

Revance Therapeutics EV-to-EBITDA Chart

Revance Therapeutics Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EV-to-EBITDA		Get a 7-Day Free Trial					-3.76	-6.70	-4.97	-5.33	-3.43

Revance Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBITDA	Get a 7-Day Free Trial															-10.23	-8.10	-3.37	-3.43	-2.51

Competitive Comparison of Revance Therapeutics's EV-to-EBITDA

For the Biotechnology subindustry, Revance Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revance Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revance Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Revance Therapeutics's EV-to-EBITDA falls into.

Revance Therapeutics EV-to-EBITDA Calculation

Revance Therapeutics's EV-to-EBITDA for today is calculated as:

Revance Therapeutics's current Enterprise Value is $545.5 Mil.
Revance Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-284.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revance Therapeutics  (NAS:RVNC) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Revance Therapeutics's PE Ratio for today is calculated as:

Revance Therapeutics's share price for today is $3.48.
Revance Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.640.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Revance Therapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Revance Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Revance Therapeutics (Revance Therapeutics) Business Description